What is the market valuation of preterm birth diagnostic test kits?

In 2027 the market for preterm birth diagnostic test kits is valued at USD 571.77 Million.

How is the preterm birth diagnostic test kits industry size expected to evolve during the forecast period?

Preterm Birth Diagnostic Test Kits Market size was worth USD 536.07 Million in 2026 and is expected to grow at 7.84% CAGR between 2027 and 2036, reaching USD 1.14 Billion by 2036.

How is demand for early pregnancy risk assessment accelerating adoption of preterm birth diagnostic kits?

Increasing focus on identifying high-risk pregnancies earlier is driving healthcare providers to adopt diagnostic kits that support timely monitoring, personalized care strategies, and improved clinical decision-making.

How are biomarker-based diagnostic advancements influencing the future of preterm birth testing?

Advances in biomarker-based approaches are improving predictive capabilities, helping clinicians identify women at higher risk and enabling more targeted monitoring throughout pregnancy management pathways.

Why does the blood sample segment lead the preterm birth diagnostic test kits market?

The blood sample segment dominated with a 42.93% share in 2026, supported by integration into clinical workflows, biomarker advancements, and growing demand for early pregnancy risk assessment.

How are diagnostic centers driving growth in the preterm birth diagnostic test kits market?

Diagnostic centers accounted for 45.58% in 2026 and are expanding rapidly due to specialized testing infrastructure, increased prenatal screening referrals, and demand for timely pregnancy risk detection.

Why does North America lead the preterm birth diagnostic test kits market?

North America led in 2026, supported by well-developed maternal healthcare infrastructure, advanced diagnostics, prenatal screening adoption, and strong clinical awareness of preterm birth risks.

How is Asia Pacific driving future market growth?

Asia Pacific is expected to grow fastest as healthcare infrastructure, maternal health awareness, prenatal diagnostic access, and investments in advanced healthcare facilities expand.

Which companies dominate the preterm birth diagnostic test kits landscape?

Prominent players in the preterm birth diagnostic test kits market include Abbott Laboratories (United States), Hologic, Inc. (United States), QIAGEN N.V. (Netherlands), CooperSurgical, Inc. (United States), Sera Prognostics, Inc. (United States), Clinical Innovations, LLC (United States), Biosynex S.A. (France), Medix Biochemica Oy (Finland), Creative Diagnostics (United States), Thermo Fisher Scientific Inc. (United States)